Online publication of the document “Q1 2024 Memorandum for modeling purposes”
Paris, France, March 22, 2024
. Sanofi announces the posting online on the Investors area of the company’s website of a document entitled “Q1 2024 Memorandum for modeling purposes”.
First quarter 2024 results – Sanofi
Like every quarter, this document aims to assist the financial community in modeling the Company’s quarterly results. This document contains a reminder of various non-recurring items and losses of exclusivity, the effect of currency variations and the number of shares. Results for the first quarter of 2024 will be announced on April 25, 2024.
About Sanofi
We are an innovative, global health company driven by a purpose: pursuing the miracles of science to improve people’s lives. Our teams, present in around a hundred countries, are working to transform the practice of medicine to make the impossible possible. We provide therapeutic solutions that can change the lives of patients and vaccines that protect millions of people around the world, guided by the ambition of sustainable development and our social responsibility.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media relations
Sandrine Guendoul
| + 33 6 25 09 14 25 |
Nicolas Obrist
| + 33 6 77 21 27 55 |
Victor Rouault
| + 33 6 70 93 71 40 |
Sally Bain
| +1 617 834 6026 |
Evan Berland
| +1 215 432 0234 | [email protected]
Investor relations
Eva Schaefer-Jansen
| + 33 7 86 80 56 39 | [email protected]
Arnaud Delépine
| + 33 6 73 69 36 93 | [email protected]
Corentine Driancourt
| + 33 6 40 56 92 21 | [email protected]
Felix Lauscher
| +1 908 612 7239 | [email protected]
Tarik Elgoutni|
+1 617 710 3587 | [email protected]
Nathalie Pham
| + 33 7 85 93 30 17 | [email protected]
Forward-looking statements
This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. These statements do not constitute historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements relating to projects, changes in scope, objectives, intentions and expectations concerning financial results, events, operations, services, future product development and their potential and statements about future performance. These forward-looking statements can often be identified by the words “expect”, “anticipate”, “believe”, “intend”, “estimate”, “plan”, “potential”, “outlook” or ” forecast”, as well as other similar terms. Although Sanofi’s management believes that these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties, which are difficult to predict and generally beyond the control of Sanofi, which may imply that the Actual results and actual events differ materially from those expressed, implied or anticipated in the forward-looking information and statements. These risks and uncertainties include in particular the uncertainties inherent in research and development, future data and clinical analyses, including post-marketing, decisions by regulatory authorities, such as the FDA or EMA, on approval. or not, and on what date, of the application for filing a drug, process or biological product for one of these product candidates, as well as their decisions relating to labeling and other factors that could affect the availability or commercial potential of these product candidates, the fact that the product candidates if approved may not achieve commercial success, the approval and future commercial success of therapeutic alternatives, Sanofi’s ability to seize external growth opportunities and finalize transactions, including on the capital markets, and to obtain the necessary regulatory authorizations, risks associated with the development of autonomous activities, ownership intellectual property and current or future litigation as well as their outcome, the evolution of exchange rates and interest rates, the instability of economic conditions and capital markets, cost control initiatives and their evolution , the impact that pandemics, political instability or armed conflict, or any other global crisis could have on Sanofi, its customers, suppliers and partners and their financial situation, as well as on its employees and on the global economy . These risks and uncertainties also include those developed or identified in public documents filed by Sanofi with the AMF and the SEC, including those listed in the “Risk Factors” and “Forward-Looking Statements” sections of the Document. Sanofi’s 2023 universal registration, which was filed with the AMF as well as in the “Risk Factors” and “Cautionary Statement Concerning Forward-Looking Statements” sections of the annual report for the financial year ended December 31, 2023 under Form 20- F from Sanofi, which was filed with the SEC. Sanofi undertakes no obligation to update forward-looking information and statements subject to applicable regulations.
Attachment